Axogen, Inc.

LSE:0HKD Stock Report

Market Cap: US$672.0m

Axogen Valuation

Is 0HKD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0HKD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$49.11
Fair Value
63.2% undervalued intrinsic discount
6
Number of Analysts

Below Fair Value: 0HKD ($18.08) is trading below our estimate of fair value ($49.11)

Significantly Below Fair Value: 0HKD is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0HKD?

Key metric: As 0HKD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0HKD. This is calculated by dividing 0HKD's market cap by their current revenue.
What is 0HKD's PS Ratio?
PS Ratio4.4x
SalesUS$180.86m
Market CapUS$672.01m

Price to Sales Ratio vs Peers

How does 0HKD's PS Ratio compare to its peers?

The above table shows the PS ratio for 0HKD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.1x
NIOX NIOX Group
6x12.1%UK£232.4m
CREO Creo Medical Group
2.4x1.3%UK£73.2m
EKF EKF Diagnostics Holdings
2.4x7.6%UK£120.2m
SN. Smith & Nephew
1.9x4.9%UK£8.6b
0HKD Axogen
4.4x10.7%US$672.0m

Price-To-Sales vs Peers: 0HKD is expensive based on its Price-To-Sales Ratio (4.4x) compared to the peer average (3.1x).

Price to Sales Ratio vs Industry

How does 0HKD's PS Ratio compare vs other companies in the GB Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
SPEC INSPECS Group
0.2x4.0%US$49.67m
YGEN Yourgene Health
0.6xn/aUS$20.48m
IHC Inspiration Healthcare Group
0.3x13.6%US$13.96m
SUN Surgical Innovations Group
0.4xn/aUS$6.84m
No more companies available in this PS range
0HKD 4.4xIndustry Avg. 2.6xNo. of Companies4PS02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0HKD is expensive based on its Price-To-Sales Ratio (4.4x) compared to the UK Medical Equipment industry average (2.6x).

Price to Sales Ratio vs Fair Ratio

What is 0HKD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0HKD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.4x
Fair PS Ratio4x

Price-To-Sales vs Fair Ratio: 0HKD is expensive based on its Price-To-Sales Ratio (4.4x) compared to the estimated Fair Price-To-Sales Ratio (4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0HKD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$18.08
US$18.50
+2.3%
6.0%US$20.00US$17.00n/a6
Jan ’26US$16.14
US$18.00
+11.5%
5.6%US$20.00US$17.00n/a6
Dec ’25US$13.89
US$17.83
+28.4%
6.0%US$20.00US$17.00n/a6
Nov ’25US$13.96
US$16.50
+18.2%
15.2%US$20.00US$12.00n/a6
Oct ’25US$14.29
US$15.83
+10.8%
16.1%US$20.00US$12.00n/a6
Sep ’25US$13.07
US$15.83
+21.1%
16.1%US$20.00US$12.00n/a6
Aug ’25US$8.30
US$13.33
+60.7%
18.7%US$17.00US$9.00n/a6
Jul ’25US$7.59
US$13.33
+75.7%
18.7%US$17.00US$9.00n/a6
Jun ’25US$6.81
US$13.40
+96.9%
20.4%US$17.00US$9.00n/a5
May ’25US$6.59
US$13.80
+109.4%
15.5%US$17.00US$11.00n/a5
Apr ’25US$7.92
US$13.80
+74.2%
15.5%US$17.00US$11.00n/a5
Mar ’25US$10.55
US$12.50
+18.5%
24.8%US$17.00US$9.00n/a5
Feb ’25US$9.82
US$12.50
+27.3%
24.8%US$17.00US$9.00n/a5
Jan ’25US$6.85
US$12.40
+81.0%
25.8%US$17.00US$9.00US$16.145
Dec ’24US$6.82
US$11.60
+70.1%
25.3%US$17.00US$9.00US$13.895
Nov ’24US$3.52
US$14.20
+303.4%
27.2%US$20.00US$9.00US$13.965
Oct ’24US$4.77
US$15.50
+225.3%
20.7%US$20.00US$11.00US$14.294
Sep ’24n/a
US$15.50
0%
20.7%US$20.00US$11.00US$13.074
Aug ’24US$8.55
US$16.25
+90.0%
15.9%US$20.00US$13.00US$8.304
Jul ’24n/a
US$16.25
0%
15.9%US$20.00US$13.00US$7.594
Jun ’24US$8.48
US$16.25
+91.6%
15.9%US$20.00US$13.00US$6.814
May ’24n/a
US$16.25
0%
15.9%US$20.00US$13.00US$6.594
Apr ’24US$9.04
US$16.25
+79.8%
15.9%US$20.00US$13.00US$7.924
Mar ’24n/a
US$16.75
0%
12.2%US$20.00US$15.00US$10.554
Feb ’24US$9.19
US$16.75
+82.2%
12.2%US$20.00US$15.00US$9.824
Jan ’24n/a
US$17.00
0%
12.5%US$20.00US$15.00US$6.854
Analyst Price Target
Consensus Narrative from 6 Analysts
US$18.53
Fair Value
2.4% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 01:48
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Axogen, Inc. is covered by 17 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael GormanBTIG
Caitlin CroninCanaccord Genuity
William PlovanicCanaccord Genuity